NYSE:NVO - Novo Nordisk A/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$50.22 +0.08 (+0.16 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$50.14
Today's Range$49.94 - $50.36
52-Week Range$41.03 - $58.37
Volume732,900 shs
Average Volume1.52 million shs
Market Capitalization$121.00 billion
P/E Ratio21.43
Dividend Yield1.85%
Beta0.68
Novo Nordisk A/S logoNovo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.77

Price-To-Earnings

Trailing P/E Ratio21.43
Forward P/E Ratio19.93
P/E Growth2.61

Sales & Book Value

Annual Sales$16.96 billion
Price / Sales7.23
Cash Flow$2.6034 per share
Price / Cash19.29
Book Value$3.10 per share
Price / Book16.20

Profitability

EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins35.21%
Return on Equity82.77%
Return on Assets40.01%

Miscellaneous

Employees42,076
Outstanding Shares2,443,530,000
Market Cap$121,003.51

The Truth About Cryptocurrencies

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a special dividend on Monday, February 5th. Investors of record on Monday, March 26th will be paid a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a yield of 0.96%. The ex-dividend date is Friday, March 23rd. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S announced that its Board of Directors has approved a share buyback plan on Friday, February 2nd 2018, which authorizes the company to buyback outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings results on Wednesday, May, 2nd. The company reported $0.73 EPS for the quarter, beating the consensus estimate of $0.69 by $0.04. The business earned $4.44 billion during the quarter, compared to analyst estimates of $4.49 billion. Novo Nordisk A/S had a return on equity of 82.77% and a net margin of 35.21%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Novo Nordisk A/S.

What is the consensus analysts' recommendation for Novo Nordisk A/S?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Has Novo Nordisk A/S been receiving favorable news coverage?

News stories about NVO stock have been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novo Nordisk A/S earned a coverage optimism score of 0.17 on Accern's scale. They also assigned news coverage about the company an impact score of 43.46 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.56%), Saratoga Research & Investment Management (0.06%), Scout Investments Inc. (0.02%), Cim LLC (0.01%), Ledyard National Bank (0.01%) and JLB & Associates Inc. (0.01%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Saratoga Research & Investment Management, World Asset Management Inc, Norman Fields Gottscho Capital Management LLC and Boston Advisors LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Scout Investments Inc., Bank of Montreal Can, JLB & Associates Inc., Ledyard National Bank and Cim LLC. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $50.22.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $121.00 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  234 (Vote Outperform)
Underperform Votes:  314 (Vote Underperform)
Total Votes:  548
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Featured Article: Earnings Per Share (EPS)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.